Alkermes Balance Sheet Health
Financial Health criteria checks 6/6
Alkermes has a total shareholder equity of $1.3B and total debt of $288.8M, which brings its debt-to-equity ratio to 22.4%. Its total assets and total liabilities are $2.2B and $863.2M respectively. Alkermes's EBIT is $318.6M making its interest coverage ratio -18.9. It has cash and short-term investments of $908.9M.
Key information
22.4%
Debt to equity ratio
US$288.82m
Debt
| Interest coverage ratio | -18.9x |
| Cash | US$908.86m |
| Equity | US$1.29b |
| Total liabilities | US$863.19m |
| Total assets | US$2.16b |
Recent financial health updates
We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt
Dec 17
Is Alkermes (NASDAQ:ALKS) A Risky Investment?
Sep 17Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Apr 08Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?
Nov 01Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?
Jul 15Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Mar 20Recent updates
We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt
Dec 17Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Nov 24Alkermes plc's (NASDAQ:ALKS) Low P/E No Reason For Excitement
Oct 14Is Alkermes (NASDAQ:ALKS) A Risky Investment?
Sep 17Alkermes: Fairly Valued After Post-Earnings Bump
Jul 28Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?
Jul 26Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry
Jul 04The Bottom Fishing Club: Alkermes Has Great Value And Safety
May 17Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals
May 08Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Apr 09Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Apr 08Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet
Jan 26Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?
Nov 01Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point
Nov 01Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?
Jul 15There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding
Jun 07Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?
Apr 10Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Mar 20Alkermes upgraded to neutral at BofA on improved risk/reward outlook
Oct 14Alkermes holder Sarissa Capital says it may look to increase its stake
Oct 07Alkermes: Nothing Stands Out As Interesting
Sep 26Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?
Aug 29Alkermes initiated at neutral at Piper Sandler as company in transition
Aug 16Alkermes Q2 2022 Earnings Preview
Jul 26Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?
Jun 27Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?
May 16Financial Position Analysis
Short Term Liabilities: ALKS's short term assets ($1.6B) exceed its short term liabilities ($453.7M).
Long Term Liabilities: ALKS's short term assets ($1.6B) exceed its long term liabilities ($409.5M).
Debt to Equity History and Analysis
Debt Level: ALKS has more cash than its total debt.
Reducing Debt: ALKS's debt to equity ratio has reduced from 26% to 22.4% over the past 5 years.
Debt Coverage: ALKS's debt is well covered by operating cash flow (123.2%).
Interest Coverage: ALKS earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 17:31 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alkermes plc is covered by 36 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Robert Hazlett | BMO Capital Markets U.S. (Historical) |
| Jason Matthew Gerberry | BofA Global Research |